CADA DIA CONTA
DA PRIORIDADE
À ACÇÃO
CANCER EVERY DAY COUNTS
FROM PRIORITY TO ACTION
26
MAIO
2021
MAY
PROGRAMA E ORADORES
AGENDA AND SPEAKERS
L I D E R A N Ç A E U R O P E I A N A S A Ú D E
Não deixar ninguém para trás
Conferência Digital & Presencial
PROGRAMA
AGENDA
8H30 - 8H45
SESSÃO DE BOAS-VINDAS ■ WELCOME SESSION
09:30
-
09:45 CET■
João Almeida Lopes, Presidente da Direção da Associação Portuguesa da
Indústria Farmacêutica (APIFARMA) |
President of the Board of the Portuguese
Pharmaceutical Industry Association (APIFARMA)
■
Marcelo Rebelo de Sousa, Presidente da República Portuguesa (mensagem
gravada) |
President of Republic of Portugal (recorded message)
8H45 - 9H15
A IMPORTÂNCIA E AS EXPECTATIVAS DO PLANO EUROPEU DE COMBATE AO CANCRO
09:45
-
10:15 CETWHY EUROPE´S BEATING CANCER PLAN IS A PRIORITY & EXPECTATIONS
■
John F. Ryan, Diretor de Saúde Pública da Direção-Geral da Saúde e Segurança
Alimentar (DG SANTE), Comissão Europeia |
Director for Public Health at
Directorate-General for Health and Food Safety (DG SANTE), European
Commission
■ Matti Aapro, Presidente da Organização Europeia de CanCro (ECO)
President of the European CanCer Organisation (ECO)
■ Ken Mastris, Presidente da Aliança Europeia de Doentes com Cancro (ECPC)
President of the European Cancer Patient Coalition (ECPC)
■ Thomas Hofmarcher, Investigador no Instituto Sueco de Economia da Saúde (IHE),
Coordenador do projeto “European Cancer Dashboard” |
Researcher Manager at the
Swedish Institute for Health Economics (IHE), Coordinator of the Project “European
Cancer Dashboard”
9H15 - 9H55
IMPACTO DA INOVAÇÃO NO DOENTE
10:15
-
10:55 CETIMPACT OF INNOVATION ON THE PATIENT
■
Fátima Cardoso, Directora da Unidade de Mama, Centro Clínico Champalimaud
da Fundação Champalimaud e Presidente ABC Global Alliance |
Director of the
Breast Unit, Champalimaud Clinical Center of Champalimaud Foundation and
President of the ABC Global Alliance
■ Rui Medeiros, Presidente da Associação
Europeia de Ligas Contra o Cancro (ECL)
President of the Association of the European Cancer Leagues (ECL)
■
Carla Bedard Pfeiffer, Vice-presidente do Grupo de Trabalho de Medicina
de Precisão na EFPIA - Federação Europeia da Indústria e Associações
Farmacêuticas |
Vice-Chair of EFPIA - European Federation of Pharmaceutical
Industries and Associations Precision Medicine Working Groups
9H55 – 10H15
COMENTÁRIOS ■ REMARKS
10:55
-
11:15 CET■
Lídia Pereira, Eurodeputada, Membro da Comissão do Ambiente, da Saúde
Pública e da Segurança Alimentar (ENVI) e da Comissão Especial sobre a Luta
Contra o Cancro (BECA) |
Member of the European Parliament, Member of
Committee on the Environment, Public Health and Food Safety (ENVI) and of
Special Committee on Beating Cancer (BECA)
■
Ana Raimundo, Presidente da Sociedade Portuguesa de Oncologia (SPO)
President of the Portuguese Society of Oncology (SPO)
10H15 – 10H20
PAUSA (EMISSÃO DE AUDIOVISUAIS)
11:15
-
11:20 CETBREAK (AUDIOVISUAL BROADCAST)
10H20 – 10H50
A ONCOLOGIA EM PORTUGAL: ONDE ESTAMOS E PARA ONDE QUEREMOS IR
11:20
-
11:50 CETONCOLOGY IN PORTUGAL: WHERE WE ARE AND WHERE WE WANT TO GO
■ Apresentação das recomendações dos grupos de reflexão sobre os 4 Pilares
(Prevenção, Diagnostico, Tratamento e Qualidade de Vida) do Plano Europeu de
Combate ao Cancro |
Presentation of the recommendations of the think tanks
on the 4 Pillars (Prevention, Diagnostic, Treatment and Quality of Life)
of the European Union Beating Cancer Plan
■ MOAI Consulting: Metodologia |
MOAI Consulting: Methodology
■ Representantes dos grupos de trabalho: Recomendações
Spokespersons of the working groups: Recommendations
10H50 – 11H35
PAINEL DEBATE: IMPLEMENTAÇÃO DA ESTRATÉGIA NACIONAL PARA O CANCRO
11:50
-
12:35 CETDEBATE PANEL: IMPLEMENTATION OF THE NATIONAL CANCER STRATEGY
■
Luís Costa, Presidente do Colégio de Oncologia Médica da Ordem dos
Médicos
President of the Medical Oncology College of the Portuguese Medical
Association
■
Vitor Rodrigues, Presidente da Liga Portuguesa contra o Cancro como
Representante das Associações de Doentes |
President of the Portuguese Cancer
League as Spokesperson of Patients’ Associations
■
José Dinis, Coordenador do Programa para as Doenças Oncológicas
Coordinator of the Oncological Diseases Programme
■
Claúdia Furtado, Diretora da Direção de Avaliação das Tecnologias da Saúde
(DATS) no INFARMED – Autoridade Nacional do Medicamento e Produtos de
Saúde |
Head of the Health Technology Assessment, Pricing and Reimbursement
Division (DATS) at INFARMED – Portuguese National Authority of Medicines and
Health Products
11H35 – 11H45
ESTRATÉGIA NACIONAL DE COMBATE AO CANCRO: A EXPERIÊNCIA DA ESLOVÉNIA**
12:35
-
12:45 CETNATIONAL CANCER BEATING STRATEGY: THE SLOVENIA EXPERIENCE**
** Próximo país a assumir a Presidência do Conselho da União Europeia
Next country to assume the Presidency of the Council of the European Union
■
Branko Zakotnik, Coordenador do Programa Nacional de Controlo do Cancro
da Eslovénia |
Coordinator of the National Cancer Control Programme (NCCP)
of Slovenia
11H45 – 12H00
CONCLUSÕES E ENCERRAMENTO
12:45
-
13:00 CETCONCLUSIONS AND CLOSING SESSION
■
João Almeida Lopes, Presidente da Direcção da Associação Portuguesa
da Indústria Farmacêutica (APIFARMA) |
President of the Board of the
Portuguese Pharmaceutical Industry Association (APIFARMA)
■
António Faria Vaz, Vice-Presidente do Conselho Diretivo do INFARMED –
Autoridade Nacional do Medicamento e Produtos de Saúde |
Vice-President of
Executive Board of INFARMED – Portuguese National Authority of Medicines and
Health Products
■
António Lacerda Sales, Secretário de Estado Adjunto e da Saúde de Portugal
Índice
Index
A iniciativa “Cancro: Cada Dia Conta – Da Prioridade
à Acção”
The initiative “Cancer: Every Day Counts - From Priority
to Action”
A Conferência de 25 de novembro de 2020
The November 25th 2020 Conference
A iniciativa “Liderança Europeia na Saúde:
Não deixar ninguém para trás”
The initiative “European Leadership in Health:
To leave no one behind
Oradores
Speakers
5
6
7
8
A iniciativa “Cancro: Cada Dia
Conta – Da Prioridade
à Acção”
O cancro é uma das principais prioridades da
Comissão Europeia no domínio das políticas
de Saúde, o que se traduzirá na aprovação de
um Plano Europeu de Combate ao Cancro e na
criação da Missão Cancro, com o objectivo de
salvar mais de 3 milhões de vidas nos próximos
10 anos, vivendo-se mais e com melhor
qualidade de vida.
Portugal preside à União Europeia (UE)
no primeiro semestre de 2021. Esta é uma
oportunidade única para estabelecer uma
plataforma de diálogo e colocar a Oncologia
como uma prioridade da Saúde em Portugal.
Em Portugal, o cancro é a patologia com a
maior carga de doença. É a principal causa
de morte antes dos 70 anos e a segunda em
termos globais.
No entanto, o investimento na sua prevenção
e no seu tratamento estão bastante abaixo da
média Europeia. Em Portugal o valor per capita
investido no tratamento do cancro é cerca de
57,5% do valor da média Europeia. Todos os anos
3,5 milhões de Europeus são diagnosticados
com cancro e 1,3 milhões morrem desta doença.
A iniciativa da APIFARMA “Cancro: Cada Dia
Conta – Da Prioridade à Acção” tem o Alto
Patrocínio de Sua Excelência O Presidente
da República e a parceria institucional de 12
Associações de Doentes.
Nasce para estabelecer uma plataforma de
diálogo para tornar a Oncologia uma prioridade
tanto no plano nacional como no europeu, para
contribuir para a definição de uma estratégia
nacional de combate ao cancro e para
contribuir encontrar soluções para os desafios
do cancro em Portugal, de forma holística,
focando-se na equidade do acesso à inovação.
The initiative “Cancer: Every
Day Counts - From Priorit
to Action”
Cancer is one of the European Commission’s
main priorities in the field of health policies,
which will translate into the approval of a
European Plan to Combat Cancer and the
creation of the Cancer Mission, to save more
than 3 million lives in the next 10 years, live
longer and with a better quality of life.
Portugal chairs the European Union (EU) in the
first half of 2021. This is a unique opportunity
to establish a platform for dialogue and place
Oncology as a priority for Health in Portugal.
In Portugal, cancer is the pathology with the
highest disease burden. It is the leading cause
of death before age 70 and the second globally.
However, investment in its prevention and
treatment is well below the European average.
In Portugal, the per capita amount invested
in cancer treatment is about 57.5% of the
European average. Every year 3.5 million
Europeans are diagnosed with ca ncer and 1.3
million dies from the disease.
The APIFARMA initiative “Cancer: Every Day
Counts - From Priority to Action” has the High
Sponsorship of His Excellency The President
of the Republic Marcelo Rebelo de Sousa and
the institutional partnership of 12 Patients’
Associations.
It was born to establish a platform for dialogue
to make Oncology a priority both at the national
and European level, contribute to the definition
of a national strategy to fight cancer, and
contribute to finding holistic solutions to cancer
challenges in Portugal, on equity in access to
innovation.
A conferência de 25
de novembro de 2020
A conferência do “Cancro: Cada dia Conta”
realizada no dia 25 de novembro de 2021 reuniu
diversos especialistas e elementos da sociedade
civil.
Um dos pontos chave desta iniciativa consistiu
na apresentação do estudo “Cancro: O que
pensam os portugueses”, realizado pela
Gfk Metris, uma avaliação da percepção da
população portuguesa sobre oncologia.
Quando questionados sobre a doença que
mais o preocupa, excluindo a Covid-19, 75%
dos inquiridos referem o Cancro como a
patologia mais preocupante, identificado
como principais razões para os receios, a
“taxa de mortalidade elevada” (25%), o facto
de “terem ou terem tido familiares com
doença oncológica/ factor hereditário” (25%),
e também o facto de esta ser uma doença
que “qualquer um pode ter” (17%).
O estudo procurou também conhecer até
que ponto o Cancro é uma prioridade para o
Governo. Cada 4 em 10 portugueses, ou seja
41%, consideram que as doenças oncológicas
têm uma maior atenção do Governo quando
comparado com a Saúde em geral. Entre os
doentes oncológicos esta perceção é mais
positiva, com 6 em cada 10 dos inquiridos,
56%, a considerarem que o cancro é uma
prioridade do Governo.
Quando questionados sobre o nível de
investimento do Estado na área do Cancro,
68% dos portugueses classificam-no de
insuficiente. Apenas 11% dos inquiridos
classificam a verba destinada ao combate ao
Cancro como justa.
Em relação aos obstáculos no acesso a
Cuidados de Saúde, 44% dos portugueses
dos portugueses identificam os tempos
de espera elevados e 15% a dificuldade em
fazer diagnósticos de forma rápida e em fase
precoce. Quanto aos tempos de espera no
acesso a tratamentos oncológicos, 25% dos
portugueses classificam a primeira consulta/
diagnóstico como muito demorada.
Outro dado preocupante refere-se à
equidade no acesso ao tratamento.
O estudo revela que mais de metade dos
portugueses considera que a qualidade e
a disponibilidade dos cuidados de saúde
variam de hospital para hospital. De acordo
com 30% dos portugueses há “grandes
diferenças com elevado impacto” e 29%
referem que há “algumas diferenças com
algum impacto”.
O estudo foca ainda os 4 Pilares do
European Union Beating Cancer Plan e
avalia a experiência pessoal dos doentes
e cuidadores, relativamente aos apoios e
pensões da Segurança Social, à experiência
com juntas médicas, ao contexto laboral
e regresso ao trabalho e aos impactos na
economia familiar.
The November 25th 2020
Conference
A “Cancer: Every Day Counts” conference held
on November 25, 2021, brought together various
experts and members of civil society.
One of the key points of this initiative was the
presentation of the study “Cancer: What the
Portuguese think”, conducted by Gfk Metris, an
assessment of the perception of the Portuguese
population about oncology.
When asked about the disease that worries
him the most, excluding Covid-19, 75% of
respondents refer to Cancer as the most
worrying pathology, identified as the main
reasons for fears, the “high mortality rate” (25%),
the fact that “they had or had family members
with oncological disease / hereditary factor”
(25%), and also the fact that this is a disease that
“anyone can have” (17%).
The study also sought to find out to what extent
Cancer is a priority for the Government. Every 4
out of 10 Portuguese, that is 41%, consider that
oncological diseases have greater attention
from the Government when compared to
Health in general. Among cancer patients, this
perception is more positive, with 6 out of 10
respondents, 56%, considering that cancer is a
priority of the Government.
When questioned about the level of Public
Investment in the Cancer beating measures,
68% of the Portuguese classify it as insufficient.
Only 11% of respondents classify the money
allocated to fight cancer as fair.
Regarding the obstacles to access to Health
Care, 44% of Portuguese identify long waiting
times and 15% the difficulty in making
diagnoses quickly and at an early stage. As for
waiting times for access to cancer treatments,
25% of Portuguese classify the first consultation/
diagnosis as very time-consuming.
Another worrying data refers to equity in access
to treatment. The study reveals that more than
half of the Portuguese believe that the quality
and availability of health care varies from
hospital to hospital. According to 30% of the
Portuguese, there are “big differences with a
high impact” and 29% say that there are “some
differences with some impact”.
The study also focuses on the 4 Pillars of the
European Union Beating Cancer Plan and
assesses the personal experience of patients
and caregivers, concerning Social Security
support and pensions, the experience with
medical boards, the work context and return to
work and the impacts on the economy familiar.
A iniciativa “Liderança
Europeia na Saúde:
Não deixar ninguém para trás”
O choque sem precedentes provocado pela
pandemia de Covid-19 tornou bem evidente os
benefícios da cooperação entre os organismos
públicos e a iniciativa privada, ao permitir uma
resposta inicial articulada, não só no combate
a este desafio, como na contenção dos seus
efeitos colaterais.
A capacidade de resposta da Europa à atual e
a futuras ameaças sanitárias será tanto mais
eficaz quanto maior a for a nossa capacidade de
afirmar este imenso território como centro de
excelência para a prática das Ciências da Vida.
A Indústria Farmacêutica está empenhada no
objetivo de aumentar a liderança da Europa na
área das Ciências da Vida, a bem de um futuro
coletivo com mais e melhor vida. O sucesso
deste nosso compromisso comum beneficiará a
vida e a longevidade dos europeus, a qualidade
com que gozamos os nossos dias e a expetativa
de um futuro melhor.
A Europa e os Sistemas de Saúde vivem um
momento que nos convoca a todos. Só uma
melhor cooperação entre todas as partes
interessadas, permitirá responder eficazmente
e com o sentido de urgência exigido.
A crise pandémica vincula-nos à insubstituível
necessidade de posicionar a Europa como
Líder na Saúde, reforça o que é hoje também
visível: conseguir atingir este objetivo também
depende da Indústria Farmacêutica e é
manifesta a necessidade de não deixar nenhum
cidadão europeu para trás.
The initiative “European
Leadership in Health:
To leave no one behind
The unprecedented shock caused by the
Covid-19 pandemic made the benefits of
cooperation between public and the private
sector very evident, by allowing an initial
response, not only in fighting this challenge but
also in containing Covid-19’s side effects.
Europe’s aptitude to respond to current and
future health threats will be all the more
effective the greater our ability to affirm this
immense territory as a center of excellence for
the practice of Life Sciences.
The Pharmaceutical Industry is committed to
the goal of increasing Europe’s leadership in the
area of Life Sciences, for the sake of a collective
future with a more and better life. The success
of our common commitment will benefit the
life and longevity of Europeans, the quality with
which we enjoy our days, and the expectation of
a better future.
Europe and its Health Systems are going
through a moment that calls us all together.
Only better cooperation between all
stakeholders will enable us to respond
effectively and with the required sense of
urgency.
The pandemic crisis links us to the irreplaceable
need to position Europe as a leader in health,
reinforces what is also visible today: achieving
this target also depends on the Pharmaceutical
Industry and the need to leave no European
citizen behind is clear.
26
MAIO
2021
MAY
ORADORES
Oradores
Speakers
8h30 – 8h45
09h30 – 09:45
CET
SESSÃO DE BOAS-VINDAS
WELCOME SESSION
MARCELO REBELO DE SOUSA
Presidente da República Portuguesa
President of Republic of Portugal
Marcelo Rebelo de Sousa was born in Lisbon, on 12 December 1948. He is a Catholic and has 2 children and 5 grandchildren. A Law Graduate, he received a Doctorate in Legal and Political Science in 1984. He was a tenured professor at the Faculty of Law of Lisbon University, and has taught throughout his career in various institutions of further education, in Portugal and abroad. He was a journalist, as editor of the Expresso newspaper between 1980 and 1983, and worked on the Seminário newspaper from 1983 to 1987. Subsequently, he appeared on the media as a political commentator on TSF radio and, later, the TV stations RTP and TVI. He works with various civic institutions and associations, as well as in the social sector, as founder, sponsor, director, or simply as a volunteer. In 1976, he served as a deputy to the Constituent Assembly. He was part of the 8th Constitutional Government as Secretary of State of the Presidency of the Council of Ministers and later, as the Minister of Parliamentary Affairs. He has supported the PSD (Social Democratic Party) since it was founded and was its president from 1996 to 1999, contributing decisively to government stability as leader of the opposition. In the international realm, he encouraged the PSD to join the European People’s Party, in which he attained the position of Vice-President. He has held various positions in local government, including Municipal Deputy, Metropolitan Deputy, Councillor and President of the Municipal Assemblies of Cascais, Lisbon, and Celorico de Basto. Marcelo Rebelo de Sousa was elected President of the Republic for the first time on 24 January 2016 and took office on 9 March. He was re-elected for a second term on 24 January 2021 and took office on 9 March of the same year.
JOÃO ALMEIDA LOPES
Presidente da Direção da Associação Portuguesa da Indústria
Farmacêutica (APIFARMA)
President of the Board of Portuguese Association of Pharmaceutical
Industry (APIFARMA)
João Almeida Lopes is Chairman of the Board of APIFARMA – Associação Portuguesa da Indústria Farmacêutica (Portuguese Pharmaceutical Industry Association) since 2007, and in 2014 became Vice-president of CIP - Confederação Empresarial de Portugal (Portuguese Business Confederation) where has
streamlined the activity of the Strategic Health Council. He was Vice-President of the Board of Health Cluster Portugal - Pólo de Competitividade da Saúde since March 2017. He has a graduation in Finance, from Instituto Superior de Economia – Lisbon, and a diversified and strong professional experience. Between 1996 and 2011 he was Vice-Chairman and Chairman of the Board of IBET – Instituto de Biologia Experimental e Tecnológica (private non-profit Biotechnology Research Organisation). Since 1990 he is General Director and Chairman of Grupo Medinfar (Portuguese Pharmaceutical Company) and, since 2008, Chairman of the Board of Genibet Biopharmaceuticals, SA (Biopharmaceutical Contract Manufacturing Organization). He has a graduation in Finance, from Instituto Superior de Economia – Lisbon, and a diversified and strong professional experience.
8H45 – 9H15
09:45 – 10:15
CET
A IMPORTÂNCIA E AS EXPECTATIVAS DO PLANO EUROPEU
DE COMBATE AO CANCRO
WHY EUROPE´S BEATING CANCER PLAN
IS A PRIORITY & EXPECTATIONS
JOHN F. RYAN
Diretor de Saúde Pública da Direção-Geral da Saúde e Segurança
Alimentar (DG SANTE), Comissão Europeia
Director for Public Health at Directorate-General for Health and Food
Safety (DG SANTE), European Commission
John Ryan has been Acting Director of the European Commission Public Health Directorate of the Directorate-General for Health and Consumers since March 2012. He is also head of the unit responsible for health threats (communicable diseases, health security and bioterrorism) within the European Commission department for public health and consumer protection. This includes responsibility for issues such as surveillance of communicable diseases, vaccination, influenza, preparedness exercises, and European Union (EU) and international cooperation on health security. In the same department, Mr Ryan was previously responsible for a variety of programmes on topics such as health information, cancer, health monitoring and promotion, rare diseases and injury prevention. He was a Commission representative on the Management Board of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and is the Commission representative on the Management Board of the European Centre for Disease Prevention and Control (ECDC). Mr Ryan has been in charge of dealing with tobacco control issues including product regulation directives, tobacco advertising and coordinating with WHO on the Framework Convention on Tobacco Control. He has previously worked in other European Commission departments dealing with the completion of the internal market, and on international trade negotiations. He is also an official of the civil service of Ireland (on leave).
MATTI AAPRO
Presidente da Organização Europeia de CanCro (ECO)
President of the European CanCer Organisation (ECO)
Matti Aapro is member of the Board of Directors of the Genolier Cancer Center, Genolier, Switzerland and President (2020-2021) of the European Cancer Organisation. He received his medical degree from the Faculty of Medicine, University of Geneva, Switzerland and was a fellow at the Arizona Cancer Center in Tucson, Arizona, USA. He was the founding chair of the Medical and Radiation Therapy Department at the European Institute of Oncology in Milan. Dr. Aapro is presently Executive Board member of the European School of Oncology (ESO). He leads the Sharing Progress in Cancer Care (SPCC) not-for-profit association. He serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He is President of Honour of the French-speaking Society for Supportive Care (AFSOS), as well as Advisor to the Japanese Association for Supportive Care in Cancer (JASCC). He has been member of the Board of the European Organization for Research and Treatment of Cancer (EORTC) and of the Board of the European Society of Medical Oncology (ESMO). He chaired the scientific and organizing committees of UICC’s (International Union against Cancer) World Cancer Congress of 2008 in Geneva, and 2010 in Shenzhen (China). He is a member of the ESMO Faculty and chaired the ESMO 2018 Supportive/ Palliative Care track. Dr. Aapro is Honorary Editor of Critical Reviews in Oncology/
for the geriatric section of the Oncologist. He is also founding editor of the Journal of Geriatric Oncology. He is past Associate Editor for Annals of Oncology, continuing on its editorial board, and member of several other editorial boards including CancerWorld. He has authored more than 350 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care. He’s Doctor Honoris Causa of the University of Tampere (2013) and Honorary Member of the Russian Society for Clinical Oncology (RUSSCO) (2016). He has received the 2010 Acta Oncologica Award, the 2012 ASCO B.J. Kennedy prize and the MASCC Distinguished Services Award (2016).
KEN MASTRIS
Presidente da Aliança Europeia de Doentes com Cancro (ECPC)
President of the European Cancer Patient Coalition (ECPC)
Representing ECPC as one of the members and promoting and working on good practices on EU and national level with collaboration with cancer patients advocates from all over Europe. Responsible for transparency and effective allocation of ECPC founding as well as supporting implementation of new projects and setting up partnerships. Before retiring in 2005, Ken worked in management for 43 years: he has been part of the Committee of management of Benenden Healthcare Society Limited and of the Board of Governors of the Hospital, but he has also been Chairman of the Internal Audit Committee and Director of the Friends of Benenden. Ken has served as Chairman of Europa Uomo. Currently, he is Chairman at couple of organisations such as Tackle Prostate Cancer UK and Association of prostate Cancer Patients in London and Essex. Ken is also involved in other organisations including EMA, EAU and ECCO. Ken Mastris is a prostate cancer patient and patient advocate, committed to promote patients’ equality in cancer treatment and better quality of life for cancer patients, in all of Europe. He is dedicated to patient advocacy and he aims to ensure that cancer patients receive the right treatment at the right time, without suffering any additional stress during complex medical procedures. He strongly believes in treating each patient as an individual, whose point of view and voice shall be carefully listened to by health professionals. Ken is also involved in educating men to recognise symptoms and signals of prostate cancer, in order to maximise the chances of early diagnosis.
THOMAS HOFMARCHER
Investigador no Instituto Sueco de Economia da Saúde (IHE), Coordenador
do projeto “European Cancer Dashboard”
Researcher Manager at the Swedish Institute for Health Economics (IHE),
Coordinator of the Project “European Cancer Dashboard”
Health economist, IHE – The Swedish Institute for Health Economics, Lund, Sweden. He holds a PhD degree in Economics from Lund University, Sweden. Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. Cancer is the disease area he has worked most with.
9H15 – 9H55
10:15 – 10:55
CET
IMPACTO DA INOVAÇÃO NO DOENTE
IMPACT OF INNOVATION ON THE PATIENT
FÁTIMA CARDOSO
Directora da Unidade de Mama, Centro Clínico Champalimaud
da Fundação Champalimaud e Presidente ABC Global Alliance
Director of the Breast Unit, Champalimaud Clinical Center of
Champalimaud Foundation and President of the ABC Global Alliance
Fátima Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal. She earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine. Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). She’s actively involved in numerous professional organizations such as ESMO, EORTC, ASCO, and AACR where she serves on several committees; she was the ESMO Transitional Director of Membership and member of the ESMO Board of Directors and was also Chair of the ESMO National Representatives Committee. She is a member of the ESMO Public Policy Steering Committee and ESMO Guidelines Steering Committee, Past Chair of the EORTC-Breast Cancer Group, member of the ASCO International Affairs Committee and ASCO Breast Cancer Guideline Advisory Group. She is also the Breast Cancer Program Coordinator of the European School of Oncology and chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC) and of the ABC Global Alliance. She’s editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals. She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology, the European Cancer Organization, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the “Fonds Jean-Claude Heuson”, the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme.
RUI MEDEIROS
Presidente da Associação Europeia de Ligas Contra o Cancro (ECL)
President of the Association of the European Cancer Leagues (ECL)
Rui is the Coordinator of the Molecular Oncology and Viral Pathology GRP of the Portuguese Oncology Institute of Porto (IPO Porto). He is also an invited Professor at the Medical School of Porto University and the Health Sciences faculty of Fernando Pessoa University. He’s also Member of the Board of the NRN-LPCC Portuguese League Against Cancer and Co-Chair of the European Cancer Organisation’s HPV Action Network. He is a member of several national and international associations and has organised, as Executive or Scientific President, some prominent international meetings and conferences, including the 30th International Papillomavirus Conference (HPV 2015), the 2nd Congress of European Society of Pharmacogenomics and Theranostics Congress (2013) and the 7th European Conference on Tobacco or Health (ECToH 2017). Dr Medeiros has authored and co-authored more than 400 peer-reviewed papers and acts as a reviewer for several scientific journals. He obtained a PhD in Human Biology, Oncology and Molecular Epidemiology from the Faculty of Medicine of Porto (FMUP) in 2002 and went on to achieve Professor status (Agregate) in 2006 at the University of Porto ICBAS Medical School. His current research and clinical interests are vaccines, viruses & Cancer Research and pharmacogenomics. He was awarded with prestigious national and International Awards and Honours, including: The European Cervical Cancer Prevention Award (European parliament/ECCA) (2009), Astellas/Yamanouchi European Foundation Award (2005); National Health Sciences Award University of Coimbra/BluePharma (2005); National Award- Portuguese Society of Human Genetics (1999) and Rotary Club Award for Oncology (1998). Rui acted as a jury member for the INFARMED Scientific Research Found. and of the Journalism Award in Oncology (Prémio Jornalismo LPCC 2015, 2016, 2017, 2018) and the Committee of the National Science Award on Oncology (Prémio Sobrinho Simões LPCC 2017).
CARLA BEDARD PFEIFFER
Vice-presidente do Grupo de Trabalho de Medicina de Precisão
na EFPIA - Federação Europeia da Indústria e Associações
Farmacêuticas
Vice-Chair of EFPIA - European Federation of Pharmaceutical
Industries and Associations Precision Medicine Working Groups
Carla Bedard is Vice-Chair of EFPIA - European Federation of Pharmaceutical Industries and Associations Precision Medicine Working Groups and works at Roche company, in Switzerland, since 2006. She’s Global Access Leader of Personalised Healthcare since 2018, EU Access Leader, Genomic Profiling & Molecular Information since 2016, and Global Leader, Innovative & Data-Enabled Access since 2014. From 2013 to 2014 she worked in Strategic Projects and Change Management, Informatics. Carla works as Investor Relations Officer from 2006 to 2010. From 2005 to 2006 she works at Bank am Bellevue AG as Senior Analyst for Biotech Equities. She also has Biotech Asset Manager from 2003 to 2005 at HBM Partners AG (Zürich). From 2000 to 2003 she divided her time between New York and London working as Biotech and Pharmaceutical Equity Research Analyst at Morgan Stanley. Previous she’s worked as
Management Consultant for Life Sciences at Ernst & Young for 2 years. She holds an AB Honors from the Brown University, Rhode Island, USA, as well an MBA in Healthcare Management from the University of Connecticut, USA.
9H55 – 10H15
10:55 – 11:15
CET
COMENTÁRIOS
REMARKS
LÍDIA PEREIRA
Eurodeputada, Membro da Comissão do Ambiente, da Saúde
Pública e da Segurança Alimentar (ENVI) e da Comissão Especial
sobre a Luta Contra o Cancro (BECA) | Member of the European
Parliament
Member of Committee on the Environment, Public Health and Food
Safety (ENVI) and of Special Committee on Beating Cancer (BECA)
Lídia Pereira has been serving as a Member of the European Parliament since 2019. She’s Member of Committee on the Environment, Public Health and Food Safety (ENVI) and of Special Committee on Beating Cancer (BECA). She’s also president of the Youth of the European People’s Party (YEPP). Pereira has a degree in Economics from the University of Coimbra and an MSc in European Economic Studies from the College of Europe. She’s also Member of UNITE - Parliamentary Network to End HIV/AIDS, Viral Hepatitis and Other Infectious Diseases, since 2019. She worked as Consultant for the financial sector, in the Compliance area.
ANA RAIMUNDO
Presidente da Sociedade Portuguesa de Oncologia (SPO)
President of the Portuguese Society of Oncology (SPO)
Ana Raimundo is Clinical Director of CUF Oncology and President of the Portuguese Oncology Society. Since 2016, she’s Assistant Graduate of Medical Oncology at the CUF Infante Santo Hospital and Assistant Graduate of Medical Oncology at the Portuguese Institute of Oncology Francisco Gentil (IPO) - Porto. She completed the Degree in Medicine, in 1994, at the University of Porto. In 1997 she started the Internship in Medical Oncology at the IPO - Porto, which she concluded in 2001. After completing the Complementary Internship in Medical Oncology, in 2002, she worked at Ludwig Institute for Cancer Research and at Saint-Luc’s Hospital, Brussels. He began his activity as a Medical Oncology Assistant at Hospital de S. João, from 2002 to 2003. From 2004 to 2016 she worked as Medical Oncology Assistant at the IPO - Porto. She’s member of ESMO – European Society for Medical Oncology, of EORTC – European Organization for Research and Treatment of Cancer (Gastrointestinal and Melanoma), of SPO – Portuguese Society of Oncology and of GICD – Digestive Cancer Research Group. She actively participates in numerous clinical trials with co-investigator and principal investigator. She has presented several scientific works as an author and co-author in several national and international meetings and congresses.
10H50 – 11H35
11:50 – 12:35
CET
PAINEL DEBATE: IMPLEMENTAÇÃO DA ESTRATÉGIA
NACIONAL PARA O CANCRO
DEBATE PANEL: IMPLEMENTATION OF THE NATIONAL
CANCER STRATEGY
LUÍS COSTA
Presidente do Colégio de Oncologia Médica da Ordem dos Médicos
President of the Medical Oncology College of the Portuguese
Medical Association
Luís Costa is Professor of Medicine at the Lisbon Medical School – University of Lisbon, Portugal and he is the head of the Clinical Translational Oncology Research Unit at IMM since 2007. Luís Costa has also served as director of the Oncology Division at Hospital de Santa Maria in Lisbon since 2005. At the School of Medicine, he is the Coordinator Professor of “Oncobiologia” a new teaching unit that aims to teach the understanding of clinical oncology through molecular medicine, and he acts as member of the Editorial board of Harvard Medical School Portugal Program. He’s the IMM Portuguese representative of the Global Cancer Genomics Consortium, as well also as an expert for grant reviews at the European Research Council, the Cancer Research UK, and CAIBER (Spanish Clinical Research Network), and the French National Cancer Institute. Luis Costa’s clinical research, publications and scientific presentations have primarily focused on bone metastases, related to breast cancer, and other solid tumours. He has published various peer-reviewed papers discussing these topics.
VÍTOR RODRIGUES
Presidente da Liga Portuguesa contra o Cancro como
Representante das Associações de Doentes
President of the Portuguese Cancer League as Spokesperson of
Patients’ Associations
Vítor Rodrigues has a degree in Medicine and a PhD in Public Health. Currently, he is an Associate Professor at the Faculty of Medicine of the University of Coimbra, in the pedagogical areas of Preventive Medicine, Epidemiology and Health Economics, being Director of the Institute of Hygiene and Social Medicine of that Faculty. In the Portuguese Cancer League, and since 1975, he has been active mainly in the area of health education and breast cancer screening.
JOSÉ DINIS
Coordenador do Programa para as Doenças Oncológicas
Coordinator of the Oncological Diseases Programme
José Dinis is Unit Coordinator and Director of the Portuguese Oncological Diseases Programme since 2019. He’s Senior Consultant for Medical Oncology at the Portuguese Institute of Oncology Francisco Gentil (IPO) – Porto since 2016 and Head of Clinical Research at the same institute since 2006. From 1999 to 2015 he was Attending Physician (Medical Oncology) at IPO - Porto. From 1994 to 1999 he was Resident (Medical Oncology) at IPO - Porto. José Dinis was Medical Intern at Hospital Geral de S. António, Porto.He completed the Degree in Medicine, in 1991, at the Institute of Biomedical Sciences Abel Salazar, University of Porto. José Dinis has presented several scientific works as an author and co-author.
CLAÚDIA FURTADO
Diretora da Direção de Avaliação das Tecnologias da Saúde (DATS)
no INFARMED – Autoridade Nacional do Medicamento e Produtos
de Saúde
Head of the Health Technology Assessment, Pricing and
Reimbursement Division (DATS) at INFARMED – Portuguese
National Authority of Medicines and Health Products
Cláudia Furtado has a Degree in Pharmaceutical Sciences, University of Lisbon and holds a PhD in Public Health from Universidade NOVA de Lisboa. Claudia Furtado is the Head of the Health Technology Assessment, Pricing and Reimbursement Division (DATS) as well of the Information and Strategic Planning Division (DIPE) at INFARMED, I.P. DATS is responsible for the HTA evaluation, pricing and reimbursement of medicines, medical devices and health products and for the managed entry agreements. DIPE is responsible for monitoring Health consumption and expenditure and for defining and evaluating policy measures. She is currently assistant professor at the Portuguese National School of Public Health (Universidade NOVA de Lisboa).
11H35 – 11H45
12:35 – 12:45
CET
ESTRATÉGIA NACIONAL DE COMBATE AO CANCRO:
A EXPERIÊNCIA DA ESLOVÉNIA
NATIONAL CANCER BEATING STRATEGY:
THE SLOVENIA EXPERIENCE
BRANKO ZAKOTNIK
Coordenador do Programa Nacional de Controlo do Cancro da
Eslovénia
Coordinator of the National Cancer Control Programme (NCCP)
of Slovenia
Branko Zakotnik is MD, PhD, medical oncologist from the Institute of Oncology in Ljubljana and the Slovene NCCP coordinator. According to epidemiological indicators, cancer is a major public health burden in Slovenia, as it is the leading cause of death among men and number two among women. Furthermore, global indicators show that cancer is a modern-day epidemic. The burden of cancer can only be systematically reduced in the long term if cancer is comprehensively controlled. For this purpose, the National Cancer Control Programme (NCCP) was established in 2010, which set goals to be achieved by 2015. In the NCCP 2010–2015 period, a slower growth in cancer incidence was achieved, more so in women than in men. During this period cancer mortality decreased for both genders and the survival rate of cancer patients in Slovenia increased compared to previous periods. The document of the NCCP 2017-2021, which was drafted in 2016 in cooperation with numerous stakeholders, defines the strategic objectives of the programme; to reduce incidence, improve survival, and provide a greater quality of life for cancer patients. The Programme’s strategic objectives can only be fulfilled through the coordinated efforts of all those segments of the healthcare system defined in the specific objectives for primary and secondary prevention, diagnostics and treatment, rehabilitation, palliative care, research, education, monitoring the burden of cancer, and information technology. In order to achieve each of these specific objectives of the Programme, measures, deadlines, and their responsible institutions have been defined. Furthermore, the NCCP 2017– 2021 also defines the updated and more operational programme management scheme that will enable a more transparent, competent, and professional control of one of the most complex systems within our healthcare structure.
11H45 – 12H00
12:45 - 13:00
CET
CONCLUSÕES E ENCERRAMENTO
CONCLUSIONS AND CLOSING SESSION
JOÃO ALMEIDA LOPES
Presidente da Direcção da Associação Portuguesa da Indústria
Farmacêutica (APIFARMA)
President of the Board of Portuguese Association of Pharmaceutical
Industry (APIFARMA)
João Almeida Lopes is Chairman of the Board of APIFARMA – Associação Portuguesa da Indústria Farmacêutica (Portuguese Pharmaceutical Industry Association) since 2007, and in 2014 became Vice-president of CIP - Confederação Empresarial de Portugal (Portuguese Business Confederation) where has streamlined the activity of the Strategic Health Council. He was Vice-President of the Board of Health Cluster Portugal - Pólo de Competitividade da Saúde since March 2017. He has a graduation in Finance, from Instituto Superior de Economia – Lisbon, and a diversified and strong professional experience. Between 1996 and 2011 he was Vice-Chairman and Chairman of the Board of IBET – Instituto de Biologia Experimental e Tecnológica (private non-profit Biotechnology Research Organisation). Since 1990 he is General Director and Chairman of Grupo Medinfar (Portuguese Pharmaceutical Company) and, since 2008, Chairman of the Board of Genibet Biopharmaceuticals, SA (Biopharmaceutical Contract Manufacturing Organization). He has a graduation in Finance, from Instituto Superior de Economia – Lisbon, and a diversified and strong professional experience.
ANTÓNIO FARIA VAZ
Vice-Presidente do Conselho Diretivo do INFARMED – Autoridade
Nacional do Medicamento e Produtos de Saúde
Vice-President of Executive Board of INFARMED – Portuguese National
Authority of Medicines and Health Products
Degree in Medicine from the Faculty of Medicine of Lisbon (1983); Specialist in General and Family Medicine (1990), Postgraduate Degree in Medicine Economics (ISEG/FFL (1995-1997); Master in Pharmacoepidemiology (2000-2005); Master in Clinical Trials (2005-2006); Master in Bioethics (2014-2018). He is Vice-President of the Directive Board of INFARMED, I.P., President of RedÉtica, President of CES of ARS LVT. He was Vice-President of CEIC (2005-2011).
ANTÓNIO LACERDA SALES
Secretário de Estado Adjunto e da Saúde de Portugal
Deputy Minister for Health of Portugal
António Lacerda Sales was a member of the Portuguese Parliament between 2015 and 2018. During this time, he coordinated the Health Committee and served as a member of the European Affairs Committee and as a substitute member of the National Defense Committee and of the Environment, Decentralization and Local Government Committee. He also took part in two Parliamentary Working Groups: Diabetes and Oncological Diseases. Orthopedist at the Santo André Hospital, of the Leiria Hospital Center, EPE, until 2015, he also practiced at S. Francisco Clinic, in Leiria, and in a private office. He has a degree in Medicine from the Faculty of Medicine of the University of Coimbra and is the author of several publications on Sports Medicine and Healthy and Active Aging.
PARCEIROS:
L I D E R A N Ç A E U R O P E I A N A
S A Ú D E
Não deixar ninguém para trás
*European Leadership in Health: To leave no one behind
